These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 29381216)

  • 1. Integrating data from the Investigational Medicinal Product Dossier/investigator's brochure. A new tool for translational integration of preclinical effects.
    van Gerven J; Cohen A
    Br J Clin Pharmacol; 2018 Jul; 84(7):1457-1466. PubMed ID: 29381216
    [No Abstract]   [Full Text] [Related]  

  • 2. The concordance between nonclinical and phase I clinical cardiovascular assessment from a cross-company data sharing initiative.
    Ewart L; Aylott M; Deurinck M; Engwall M; Gallacher DJ; Geys H; Jarvis P; Ju H; Leishman D; Leong L; McMahon N; Mead A; Milliken P; Suter W; Teisman A; Van Ammel K; Vargas HM; Wallis R; Valentin JP
    Toxicol Sci; 2014 Dec; 142(2):427-35. PubMed ID: 25246669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Commentary on the EMA Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products.
    van Gerven J; Bonelli M
    Br J Clin Pharmacol; 2018 Jul; 84(7):1401-1409. PubMed ID: 29451320
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparative requirements for exploratory clinical trials -- eIND, eCTA and microdosing.
    Muller PY
    Adv Drug Deliv Rev; 2011 Jun; 63(7):511-7. PubMed ID: 21034787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Animal models: Mouse already being charted gene by gene.
    Brown S
    Nature; 2014 Apr; 508(7496):319. PubMed ID: 24740057
    [No Abstract]   [Full Text] [Related]  

  • 6. [From molecule to medicine--drug development].
    Bruhn C
    Dtsch Med Wochenschr; 2010 Feb; 135(6):p5. PubMed ID: 20151355
    [No Abstract]   [Full Text] [Related]  

  • 7. [Preclinical research. Seal of approval translational medicine].
    Hermann S; Pichler B; Kotzerke J
    Nuklearmedizin; 2013 Dec; 52(6):N53-4. PubMed ID: 24337015
    [No Abstract]   [Full Text] [Related]  

  • 8. Preclinical research: Make mouse studies work.
    Perrin S
    Nature; 2014 Mar; 507(7493):423-5. PubMed ID: 24678540
    [No Abstract]   [Full Text] [Related]  

  • 9. Regulatory considerations for preclinical development of anticancer drugs.
    DeGeorge JJ; Ahn CH; Andrews PA; Brower ME; Giorgio DW; Goheer MA; Lee-Ham DY; McGuinn WD; Schmidt W; Sun CJ; Tripathi SC
    Cancer Chemother Pharmacol; 1998; 41(3):173-85. PubMed ID: 9443633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical predictors of clinical safety: opportunities for improvement.
    Sistare FD; DeGeorge JJ
    Clin Pharmacol Ther; 2007 Aug; 82(2):210-4. PubMed ID: 17507920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing translational population-PBPK modelling of brain microdialysis with bottom-up prediction of brain-to-plasma distribution in rat and human.
    Ball K; Bouzom F; Scherrmann JM; Walther B; Declèves X
    Biopharm Drug Dispos; 2014 Nov; 35(8):485-99. PubMed ID: 25044007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 0 trials: a platform for drug development?
    Lancet; 2009 Jul; 374(9685):176. PubMed ID: 19616703
    [No Abstract]   [Full Text] [Related]  

  • 13. Toxicology testing in drug discovery and development.
    Dorato MA; Buckley LA
    Curr Protoc Toxicol; 2007 Feb; Chapter 19():Unit19.1. PubMed ID: 23045141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New strategy for drug development with exploratory IND studies: scientific basis and future directions.
    Yamashita S; Sugiyama Y
    Adv Drug Deliv Rev; 2011 Jun; 63(7):493. PubMed ID: 21601603
    [No Abstract]   [Full Text] [Related]  

  • 15. The case for introducing pre-registered confirmatory pharmacological pre-clinical studies.
    Kiwanuka O; Bellander BM; Hånell A
    J Cereb Blood Flow Metab; 2018 May; 38(5):749-754. PubMed ID: 29480040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What constitutes scientific justification for inclusion of recovery assessment in pre-clinical studies supporting first time in man (FTIM)?
    Robinson S; Roberts R
    Regul Toxicol Pharmacol; 2014 Nov; 70(2):572-3. PubMed ID: 25223564
    [No Abstract]   [Full Text] [Related]  

  • 17. Reverse translation of failed treatments can help improving the validity of preclinical animal models.
    't Hart BA
    Eur J Pharmacol; 2015 Jul; 759():14-8. PubMed ID: 25823810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How to Interpret an Investigator's Brochure for Meaningful Risk Assessment: Results of an AGAH Discussion Forum.
    Rengelshausen J; Breithaupt-Groegler K; Donath F; Erb-Zohar K; Hardman T; Mikus G; Plassmann S; Wensing G; Sourgens H
    Ther Innov Regul Sci; 2021 May; 55(3):612-618. PubMed ID: 33537954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety, efficacy and regulatory triangle in drug development: Impact for animal models and the use of animals.
    van Meer PJ; Graham ML; Schuurman HJ
    Eur J Pharmacol; 2015 Jul; 759():3-13. PubMed ID: 25818943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [An evaluation of non-clinical animal data from the point of view of a clinical pharmacologist].
    Uchida E
    Nihon Yakurigaku Zasshi; 1999 Jan; 113(1):47-53. PubMed ID: 10096105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.